G1 reports Phase IIa data for trilaciclib as first-line treatment of SCLC

G1 Therapeutics Inc. (NASDAQ:GTHX) reported top-line data from 77 treatment-naïve patients with extensive-stage small cell lung cancer (SCLC) in the double-blind Phase IIa portion of

Read the full 259 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE